LOS ANGELES, CA--(Marketwired - Mar 23, 2017) - Endonovo Therapeutics, Inc. (
The non-provisional patent application follows the Company's on-going research and development into the development of a novel class of non-invasive therapeutics known as electroceuticals.
"We are very excited about our new generation of non-invasive electroceuticals developed specifically to target vascular diseases and ischemic injuries," stated Endonovo Chairman and CEO, Alan Collier.
"We believe that this new technology is vastly superior to the original technology, initially developed at NASA, which was higher powered and originally designed for bone healing. Our new signal, which we will be using in our entire pipeline targeting vascular diseases and ischemic injuries, was developed using our scientific team's twenty plus year experience in researching and developing electrical and bioelectromagnetic therapeutics," concluded Mr. Collier.
The Company is evaluating the therapeutic potential of its new electroceutical technology in prevention of heart failure following myocardial infarction. The Company now anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017.
About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a leading developer of bioelectronic-enhanced cell therapies and non-invasive electroceuticals. Endonovo's Immunotronics™ platform is dedicated to treating patients with vascular diseases and life-threatening inflammatory conditions in vital organs using proprietary non-invasive electroceutical devices. The Company's non-invasive platform is based on magnetically-induced electrical field pathways that target the disruption of inflammation and cell death.
The Company's Cytotronics™ platform harnesses the bulk electrical properties of cells and tissues, namely magnetically-induced electrical field pathways to expand and enhance the therapeutic potential of cell therapies and produce next-generation biologics.
Safe Harbor Statement This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investors: Sign Up for Email Alerts on Endonovo
Investor Relations Contact: Endonovo Therapeutics, Inc. Mr. Steven Barnes Senior Vice President of Investor Relations (800) 701-1223, Ext. 108 Sbarnes@endonovo.com www.endonovo.com
